Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010 (2010), Article ID 135354, 8 pages
http://dx.doi.org/10.1155/2010/135354
Research Article

Thrombopoietin Receptor Levels in Tumor Cell Lines and Primary Tumors

1Oncology Biology, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426-2990, USA
2Oncology Biomarkers, GlaxoSmithKline, Morphotek, 210 Welsh Pool Road, Exton, PA 19341, USA
3Oncology Clinical, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
4Oncology Biomarkers, GlaxoSmithKline, Astellas Pharmaceuticals, 3 Parkway North, Deerfield, IL 60015, USA
5Oncology Clinical, GlaxoSmithKline, Oncology R&D, Building 11, 1-3 Bridge Road, Stockley Park West, Uxbridge, Middlesex UB11 1BT, UK
6Oncology Biomarkers, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426-2990, USA
7Oncology Clinical, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426-2990, USA

Received 3 June 2010; Accepted 24 September 2010

Academic Editor: Edgar Selzer

Copyright © 2010 Connie L. Erickson-Miller et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. C. Broudy, N. L. Lin, and K. Kaushansky, “Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro,” Blood, vol. 85, no. 7, pp. 1719–1726, 1995. View at Google Scholar · View at Scopus
  2. F. J. de Sauvage, K. Carver-Moore, S.-M. Luoh et al., “Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin,” Journal of Experimental Medicine, vol. 183, no. 2, pp. 651–656, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. V. R. Deutsch and A. Tomer, “Megakaryocyte development and platelet production,” British Journal of Haematology, vol. 134, no. 5, pp. 453–466, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Kaushansky, V. C. Broudy, N. Lin et al., “Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 8, pp. 3234–3238, 1995. View at Google Scholar · View at Scopus
  5. D. J. Kuter and R. D. Rosenberg, “Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit,” Blood, vol. 84, no. 5, pp. 1464–1472, 1994. View at Google Scholar · View at Scopus
  6. K. Peeters, J.-M. Stassen, D. Collen, C. Van Geet, and K. Freson, “Emerging treatments for thrombocytopenia: increasing platelet production,” Drug Discovery Today, vol. 13, no. 17-18, pp. 798–806, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. P. J. Ballem, A. Belzberg, D. V. Devine et al., “Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection,” The New England Journal of Medicine, vol. 327, no. 25, pp. 1779–1784, 1992. View at Google Scholar · View at Scopus
  8. S. P. Lawrence, D. C. Lezotte, J. D. Durham, D. A. Kumpe, G. T. Everson, and B. M. Bilir, “Course of thrombocytopenia of chronic liver disease after transjugular intrahepatic portosystemic shunts (TIPS). A retrospective analysis,” Digestive Diseases and Sciences, vol. 40, no. 7, pp. 1575–1580, 1995. View at Publisher · View at Google Scholar
  9. A. H. Lazarus, J. Ellis, J. W. Semple, M. Mody, A. R. Crow, and J. Freedman, “Comparison of platelet immunity in patients with SLE and with ITP,” Transfusion Science, vol. 22, no. 1-2, pp. 19–27, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Mittelman, “Platelet function in the myelodysplastic syndromes,” International Journal of Hematology, vol. 71, no. 2, pp. 95–98, 2000. View at Google Scholar · View at Scopus
  11. L. S. Elting, E. B. Rubenstein, C. G. Martin et al., “Incidence, cost, and outcomes of bleeding and chemotherapy dose modificaton among solid tumor patients with chemotherapy-induced thrombocytopenia,” Journal of Clinical Oncology, vol. 19, no. 4, pp. 1137–1146, 2001. View at Google Scholar
  12. J. M. Jenkins, D. Williams, Y. Deng et al., “Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist,” Blood, vol. 109, no. 11, pp. 4739–4741, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. V. C. Broudy and N. L. Lin, “AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl,” Cytokine, vol. 25, no. 2, pp. 52–60, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. C. L. Erickson-Miller, E. DelOrme, S.-S. Tian et al., “Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist,” Stem Cells, vol. 27, no. 2, pp. 424–430, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. J. A. Erhardt, C. L. Erickson-Miller, M. Aivado, M. Abboud, K. Pillarisetti, and J. R. Toomey, “Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function,” Experimental Hematology, vol. 37, no. 9, pp. 1030–1037, 2009. View at Publisher · View at Google Scholar
  16. F. Merchionne and F. Dammacco, “Biological functions and therapeutic use of erythropoiesis-stimulating agents: perplexities and perspectives,” British Journal of Haematology, vol. 146, no. 2, pp. 127–141, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. M. Newland and C. D. Black, “Tumor progression associated with erythropoiesis-stimulating agents,” Annals of Pharmacotherapy, vol. 42, no. 12, pp. 1865–1870, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Wetzler, S. H. Bernstein, H. Baumann et al., “Expression and function of the megakaryocyte growth and development factor receptor in acute myeloid leukemia blasts,” Leukemia and Lymphoma, vol. 30, no. 5-6, pp. 415–431, 1998. View at Google Scholar · View at Scopus
  19. T. Motoji, M. Takanashi, S. Motomura et al., “Growth stimulatory effect of thrombopoietin on the blast cells of acute myelogenous leukaemia,” British Journal of Haematology, vol. 94, no. 3, pp. 513–516, 1996. View at Google Scholar · View at Scopus
  20. T. Murayama, S. Imoto, T. Natazuka, K. Chihara, and T. Matsui, “Proliferative reaction of myelogenous leukemia cells with cytokines G-CSF, GM-CSF, M-CSF, SCF and TPO,” Leukemia Research, vol. 22, no. 6, pp. 557–560, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Tafuri, R. M. Lemoli, M. T. Petrucci et al., “Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells,” Experimental Hematology, vol. 27, no. 8, pp. 1255–1263, 1999. View at Publisher · View at Google Scholar
  22. B. Will, M. Kawahara, J. P. Luciano et al., “Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome,” Blood, vol. 114, no. 18, pp. 3899–3908, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. C. L. Erickson-Miller, J. Kirchner, M. Aivado, R. May, P. Payne, and A. Chadderton, “Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag,” Leukemia Research, vol. 34, no. 9, pp. 1224–1231, 2010. View at Publisher · View at Google Scholar
  24. I. Mavroudi, K. Pyrovolaki, K. Pavlaki et al., “Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome,” Leukemia Research, 2010, In Press. View at Publisher · View at Google Scholar
  25. C. L. Erickson-Miller, K. Pillarisetti, J. Kirchner et al., “Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovary,” submitted.
  26. R. A. Irizarry, B. Hobbs, F. Collin et al., “Exploration, normalization, and summaries of high density oligonucleotide array probe level data,” Biostatistics, vol. 4, no. 2, pp. 249–264, 2003. View at Google Scholar · View at Scopus
  27. D. F. Stroncek and P. Rebulla, “Platelet transfusions,” The Lancet, vol. 370, no. 9585, pp. 427–438, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Tóvári, R. Pirker, J. Tímár, G. Ostoros, G. Kovács, and B. Döme, “Erythropoietin in cancer: an update,” Current Molecular Medicine, vol. 8, no. 6, pp. 481–491, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. M. O. Arcasoy, “Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives,” Clinical Cancer Research, vol. 14, no. 15, pp. 4685–4690, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. A. M. Sinclair, M. D. Todd, K. Forsythe, S. J. Knox, S. Elliott, and C. G. Begley, “Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients,” Cancer, vol. 110, no. 3, pp. 477–488, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Werner and I. Bruchim, “The insulin-like growth factor-I receptor as an oncogene,” Archives of Physiology and Biochemistry, vol. 115, no. 2, pp. 58–71, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt, “The role of the IGF system in cancer growth and metastasis: overview and recent insights,” Endocrine Reviews, vol. 28, no. 1, pp. 20–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Sotiriou and L. Pusztai, “Gene-expression signatures in breast cancer,” The New England Journal of Medicine, vol. 360, no. 8, pp. 752–800, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. A. M. Sinclair, N. Rogers, L. Busse et al., “Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells,” British Journal of Cancer, vol. 98, no. 6, pp. 1059–1067, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Laugsch, E. Metzen, T. Svensson, R. Depping, and W. Jelkmann, “Lack of functional erythropoietin receptors of cancer cell lines,” International Journal of Cancer, vol. 122, no. 5, pp. 1005–1011, 2008. View at Publisher · View at Google Scholar · View at Scopus